

Reference for the First Quarter of FYE 2023 Consolidated Financial Results

(Yen in 100 millions. Units in thousands)

						· · · · · · · · · · · · · · · · · · ·	100 millions,		ousands)
		FYE 2022 FYE 2023			FYE 2022 FYE 2023				
		1st Quarter		st Qarter		Full Year		Full Year	_
		[2021. 4–6]	_	022. 4–6]		['21.4 – '22.3]	[2022.4 – 2023.3]		
		RESULTS	R	RESULTS		RESULTS	ULTS FORECASTS		
				Change	%			Change	%
Revenue		6,352	8,341	1,989	31.3	27,445	35,000	7,555	27.5
	Japan	1,130	1,271	140	12.4	4,880	-	_	-
	Overseas	5,222	7,070	1,849	35.4	22,565	-	-	-
Operating profit (loss)		295	370	74	25.2	905	2,000	1,095	121.1
. 01	Profit margin (%)	4.6	4.4			3.3		,	
Profit (loss) before tax	0 ()	343	384	42	12.1	1,070	2,000	930	87.0
Profit margin (%)		5.4	4.6			3.9	5.7		
Profit (loss) for the period attributable		185	272	87	47.0	700	1,400	700	100.0
to owners of parent	Profit margin (%)	2.9	3.3	<u> </u>		2.6	<u> </u>		
to owners or parent	Troncinaight (70)	2.5	Effects of fo	reign	444		Sales volun	ne, mix,	
Factors contributing to			exchange rates Sales volume, mix, 112			etc.		2,365	
change in operating profit						Effects of fo	•	859	
		/	etc.				exchange ra Increase in		
		/	Decrease in	R&D exp.	2	/	exp., etc.	JUAN	(1,006
		/	Increase in	SG&A	(220)		•	te.	(007
		/	exp., etc.		(338)		Cost impac	เอ	(987
		/	Cost impact	ts	(158)		Increase in	R&D exp.	(156)
		/	•					•	
			Other		12		Other		20
Exchange rates JPY/US\$		109/US\$	125/US\$			112/US\$	120/US\$		
JPY/EUR		131/EUR	134/EUR			130/EUR	130/EUR		
Capital expenditures		192	280			861	1,400		
Depreciation		228	238			946	1,000		
R&D expenditures *		271	231			1,138	1,200		
Interest bearing debts		3,360	3,314			3,340	-		
interest bearing debts		0,000	- Increase in revenue for two			0,040	- First increase in revenue in three		
Performance description			consecutive years - Increase in profit at each stage				years - First increase in revenue in three years - First increase in profit at each stage in three years		
			for two consecutive years						
			•						
			- Increase in consolidated unit sales for two consecutive years				 First increase in consolidated unit sales in three years 		
Consolidated unit sales		24			-	/			20.0
		24	20	(4)	(14.8)	89	115	25	28.2
< Japan >	Passenger Cars	19	16	(3)	(14.4)	73	91	18	25.4
Onneallated : 11	Minicars	5	4	(1)	(16.5)	17	24	7	40.1
Consolidated unit sales		151	175	24	15.9	645	826	181	28.1
< Overseas >	North America	129	150	21	16.2	555	688	133	24.0
	Europe **	3	5	1	37.0	15	-	-	-
	China	4	3	(1)	(25.3)	14	19	5	37.0
	Other	15	18	3	19.3	60	-	-	-
Consolidated unit sales total		175	196	21	11.7	734	940	206	28.1
		184	205	22	11.7	727	1,000	273	37.6
Production units total				4.0	450	455			/
Production units total	Japan	117	135	18	15.3	455			
Production units total	Japan U.S.		135 70	18 4	5.4	455 272			
	· · · · · · · · · · · · · · · · · · ·	117							
Revenue by	U.S.	117 67	70	4	5.4	272		/	
	U.S. Automobile Aerospace	117 67 6,177 163	70 8,181 148	2,004 (15)	5.4 32.4 (9.0)	272 26,775 623			
Revenue by	U.S. Automobile Aerospace Other	117 67 6,177 163 12	70 8,181 148 12	2,004 (15) 0	5.4 32.4 (9.0) 1.9	272 26,775 623 48			
Revenue by business segment	U.S. Automobile Aerospace	117 67 6,177 163 12 287	70 8,181 148 12 364	2,004 (15) 0 77	5.4 32.4 (9.0)	272 26,775 623 48 925			
Revenue by business segment Operating profit (loss)	U.S. Automobile Aerospace Other	117 67 6,177 163 12	70 8,181 148 12	2,004 (15) 0	5.4 32.4 (9.0) 1.9	272 26,775 623 48			
Revenue by business segment Operating profit (loss) by business	U.S. Automobile Aerospace Other Automobile	117 67 6,177 163 12 287	70 8,181 148 12 364	2,004 (15) 0 77	5.4 32.4 (9.0) 1.9 26.8	272 26,775 623 48 925			
Revenue by business segment Operating profit (loss)	U.S. Automobile Aerospace Other Automobile Aerospace	117 67 6,177 163 12 287 (8)	70 8,181 148 12 364 (21)	2,004 (15) 0 77 (12)	5.4 32.4 (9.0) 1.9	272 26,775 623 48 925 (70)			

^{* &}quot;R&D expenditures" indicate R&D activity related costs incurred during the reporting period. Under IFRS, a part of these costs that meets capitalization criteria is recognized as an intangible asset and amortized over its estimated useful life; thus, the amount of "R&D expenditures" stated here does not match that of "R&D expenses" stated on the Consolidated Statement of Income.

^{**} Starting from the August 3, 2022 reporting, the regions under "Europe" have been redefined. (The figures of the previous-year results have been changed accordingly.)

< Forward-looking statements in this document are based on the information available at the time of the announcement and are subject to various risks and uncertainties that could cause actual results to vary materially. >